October 9, 2016
Novartis: exploring Zykadia’s efficacy in ALK+ NSCLC patients grows
Novartis today announced updated results from a Phase II study (ASCEND-3), which demonstrated that anaplastic lymphoma kinase-positive (ALK+) non-small cell…